How to buy Annovis Bio stock | $28.89

Annovis Bio Inc is a biotechnology business based in the US. Annovis Bio shares (ANVS) are listed on the NYSE MKT and all prices are listed in US Dollars. Annovis Bio employs 2 staff and has a market cap (total outstanding shares value) of 0.00.

Annovis Bio stock price (NYSE MKT: ANVS)

Use our graph to track the performance of ANVS stocks over time.

Annovis Bio shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$28.89
52-week range	$4.20 - $132.00
50-day moving average	$32.24
200-day moving average	$49.99
Wall St. target price	$70.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.20

Buy Annovis Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Annovis Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Annovis Bio price performance over time

Historical closes compared with the close of $28.89 from 2021-10-22

1 week (2021-10-15)	3.22%
1 month (2021-09-23)	-18.46%
3 months (2021-07-23)	-75.72%
6 months (2021-04-23)	25.61%

1 year (2020-10-23)	469.82%
2 years (2019-10-19)	N/A
3 years (2018-10-19)	N/A
5 years (2016-10-19)	N/A

Annovis Bio financials

Gross profit TTM	$0
Return on assets TTM	-19.42%
Return on equity TTM	-29.03%
Profit margin	0%
Book value	$6.01
Market capitalisation	$226.7 million

TTM: trailing 12 months

Shorting Annovis Bio shares

There are currently 370,374 Annovis Bio shares held short by investors – that's known as Annovis Bio's "short interest". This figure is 2% down from 378,091 last month.

There are a few different ways that this level of interest in shorting Annovis Bio shares can be evaluated.

Annovis Bio's "short interest ratio" (SIR)

Annovis Bio's "short interest ratio" (SIR) is the quantity of Annovis Bio shares currently shorted divided by the average quantity of Annovis Bio shares traded daily (recently around 209250.84745763). Annovis Bio's SIR currently stands at 1.77. In other words for every 100,000 Annovis Bio shares traded daily on the market, roughly 1770 shares are currently held short.

However Annovis Bio's short interest can also be evaluated against the total number of Annovis Bio shares, or, against the total number of tradable Annovis Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Annovis Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Annovis Bio shares in existence, roughly 50 shares are currently held short) or 0.0671% of the tradable shares (for every 100,000 tradable Annovis Bio shares, roughly 67 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Annovis Bio.

Find out more about how you can short Annovis Bio stock.

Annovis Bio share dividends

We're not expecting Annovis Bio to pay a dividend over the next 12 months.

Annovis Bio overview

Annovis Bio, Inc. , a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania. .

Frequently asked questions

What percentage of Annovis Bio is owned by insiders or institutions?
Currently 30.385% of Annovis Bio shares are held by insiders and 19.601% by institutions. How many people work for Annovis Bio?
Latest data suggests 2 work at Annovis Bio. When does the fiscal year end for Annovis Bio?
Annovis Bio's fiscal year ends in December. Where is Annovis Bio based?
Annovis Bio's address is: 1055 Westlakes Drive, Berwyn, PA, United States, 19312 What is Annovis Bio's ISIN number?
Annovis Bio's international securities identification number is: US03615A1088 What is Annovis Bio's CUSIP number?
Annovis Bio's Committee on Uniform Securities Identification Procedures number is: 03615A108